JP2016540738A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016540738A5 JP2016540738A5 JP2016526801A JP2016526801A JP2016540738A5 JP 2016540738 A5 JP2016540738 A5 JP 2016540738A5 JP 2016526801 A JP2016526801 A JP 2016526801A JP 2016526801 A JP2016526801 A JP 2016526801A JP 2016540738 A5 JP2016540738 A5 JP 2016540738A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- prostate cancer
- pharmaceutical composition
- composition according
- akr1c3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010060862 Prostate cancer Diseases 0.000 claims description 85
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 85
- 239000003112 inhibitor Substances 0.000 claims description 76
- 108091008721 AR-V7 Proteins 0.000 claims description 42
- 239000000203 mixture Substances 0.000 claims description 21
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 18
- 229960003668 docetaxel Drugs 0.000 claims description 18
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical group CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 18
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 claims description 17
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 claims description 17
- 229960000853 abiraterone Drugs 0.000 claims description 17
- 229960000997 bicalutamide Drugs 0.000 claims description 17
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 claims description 17
- 229960004671 enzalutamide Drugs 0.000 claims description 17
- RJMUSRYZPJIFPJ-UHFFFAOYSA-N niclosamide Chemical group OC1=CC=C(Cl)C=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1Cl RJMUSRYZPJIFPJ-UHFFFAOYSA-N 0.000 claims description 17
- 229960001920 niclosamide Drugs 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 14
- 230000002280 anti-androgenic effect Effects 0.000 claims description 13
- 239000000051 antiandrogen Substances 0.000 claims description 13
- 239000003560 cancer drug Substances 0.000 claims description 10
- 229960000905 indomethacin Drugs 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 9
- 230000008901 benefit Effects 0.000 claims description 6
- 230000001394 metastastic effect Effects 0.000 claims description 4
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 102000004602 Aldo-Keto Reductase Family 1 Member C3 Human genes 0.000 claims 14
- 108010065942 Prostaglandin-F synthase Proteins 0.000 claims 14
- 230000002708 enhancing effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 43
- 108010080146 androgen receptors Proteins 0.000 description 8
- 102000001307 androgen receptors Human genes 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000003183 carcinogenic agent Substances 0.000 description 5
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 102000005602 Aldo-Keto Reductases Human genes 0.000 description 1
- 108010084469 Aldo-Keto Reductases Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019116833A JP6974392B2 (ja) | 2013-10-28 | 2019-06-25 | 転移性前立腺癌の治療 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361896250P | 2013-10-28 | 2013-10-28 | |
| US61/896,250 | 2013-10-28 | ||
| US201361914389P | 2013-12-11 | 2013-12-11 | |
| US61/914,389 | 2013-12-11 | ||
| PCT/US2014/062455 WO2015065919A1 (en) | 2013-10-28 | 2014-10-27 | Treatment of metastatic prostate cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019116833A Division JP6974392B2 (ja) | 2013-10-28 | 2019-06-25 | 転移性前立腺癌の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016540738A JP2016540738A (ja) | 2016-12-28 |
| JP2016540738A5 true JP2016540738A5 (OSRAM) | 2017-11-30 |
| JP6548641B2 JP6548641B2 (ja) | 2019-07-24 |
Family
ID=53004994
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016526801A Expired - Fee Related JP6548641B2 (ja) | 2013-10-28 | 2014-10-27 | 転移性前立腺癌の治療 |
| JP2019116833A Expired - Fee Related JP6974392B2 (ja) | 2013-10-28 | 2019-06-25 | 転移性前立腺癌の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019116833A Expired - Fee Related JP6974392B2 (ja) | 2013-10-28 | 2019-06-25 | 転移性前立腺癌の治療 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20170315127A1 (OSRAM) |
| EP (1) | EP3062808B1 (OSRAM) |
| JP (2) | JP6548641B2 (OSRAM) |
| CN (1) | CN105899223A (OSRAM) |
| WO (1) | WO2015065919A1 (OSRAM) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011002988A1 (en) | 2009-07-01 | 2011-01-06 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for severe combined immunodeficiency (scid) |
| CN105899223A (zh) | 2013-10-28 | 2016-08-24 | 加利福尼亚大学董事会 | 转移性前列腺癌的治疗 |
| EP3146081B1 (en) * | 2014-05-19 | 2020-10-28 | The Johns Hopkins University | Methods for identifying androgen receptor splice variants in subjects having castration resistant prostate cancer |
| ES2863500T3 (es) | 2015-04-10 | 2021-10-11 | Capsugel Belgium Nv | Formulaciones lipídicas de acetato de abiraterona |
| WO2016179002A1 (en) * | 2015-05-01 | 2016-11-10 | The Regents Of The University Of California | Compositions and methods for treatment of cancer |
| AU2016315852B2 (en) * | 2015-09-01 | 2023-06-15 | First Wave Bio, Inc. | Methods and compositions for treating conditions associated with an abnormal inflammatory responses |
| JP2018535190A (ja) * | 2015-09-16 | 2018-11-29 | エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ | Ｐ５３欠損細胞の治療におけるニクロサミドの使用 |
| EP3359692A4 (en) * | 2015-10-05 | 2019-05-01 | Cedars-Sinai Medical Center | METHOD FOR CLASSIFYING AND TREATING CANCER |
| WO2017120218A1 (en) * | 2016-01-04 | 2017-07-13 | The Regents Of The University Of Colorado, A Body Corporate | Treatment of prostate cancer cells with fat oxidation inhibitors and enzalutamide |
| WO2017210117A1 (en) * | 2016-06-02 | 2017-12-07 | Board Of Trustees, Southern Illinois University | Treatment of endometriosis and niclosamide derivatives |
| WO2017207702A1 (en) * | 2016-06-02 | 2017-12-07 | Sint-Augustinus | Androgen receptor splice variants and androgen deprivation therapy |
| US20200031848A1 (en) | 2016-12-19 | 2020-01-30 | Hoffmann-La Roche Inc. | Ar-v7 inhibitors |
| WO2018136650A1 (en) * | 2017-01-19 | 2018-07-26 | The Regents Of The University Of California | Compositions and methods for treating androgen-independent cancer |
| US20210092942A1 (en) * | 2017-03-31 | 2021-04-01 | Hera Testing Laboratories, Inc. | Novel immunodeficient rat for modeling human cancer |
| RU2696288C2 (ru) * | 2017-10-16 | 2019-08-01 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Кировский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Кировский ГМУ Минздрава России) | Способ лечения кастрационно-устойчивого рака простаты |
| RU2673816C1 (ru) * | 2017-10-16 | 2018-11-30 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Кировский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Кировский ГМУ Минздрава России) | Способ лечения кастрационно-устойчивого рака простаты |
| CN111655249A (zh) | 2017-11-14 | 2020-09-11 | 蒙彼利埃地区癌症研究所 | 用于治疗前列腺癌的活性物的组合 |
| CN109836499A (zh) * | 2017-11-27 | 2019-06-04 | 益善生物技术股份有限公司 | 抗人雄激素受体剪接变异体7的单克隆抗体及其应用 |
| CN108187067A (zh) * | 2018-01-09 | 2018-06-22 | 中国人民解放军第三0九医院 | ITCNs组装体负载抗肿瘤化合物的应用 |
| WO2019155416A2 (en) * | 2018-02-09 | 2019-08-15 | Kashiv Pharma Llc | A stable pharmaceutical composition of poorly soluble nonsteroidal antiandrogens |
| CN110693892A (zh) * | 2018-07-09 | 2020-01-17 | 深圳艾欣达伟医药科技有限公司 | 化合物用于制备预防、治疗或改善疼痛的药物的用途 |
| CN113056267A (zh) * | 2018-08-26 | 2021-06-29 | 凯帝夫肿瘤科技有限公司 | Plk1靶磷酸化状态以及用plk1抑制剂治疗癌症 |
| WO2020051294A1 (en) * | 2018-09-07 | 2020-03-12 | Karyopharm Therapeutics Inc. | The combination of xpo1 inhibitors and second agents for the treatment of prostate cancer |
| TWI816880B (zh) * | 2018-09-13 | 2023-10-01 | 大陸商恒翼生物醫藥（上海）股份有限公司 | 治療前列腺癌之組合療法 |
| CN109234393A (zh) * | 2018-09-30 | 2019-01-18 | 上海交通大学医学院附属仁济医院 | 一种用于检测转移性去势抵抗性前列腺癌的基因探针组合物及试剂盒 |
| WO2020092972A1 (en) * | 2018-11-01 | 2020-05-07 | The Regents Of The University Of California | Compounds, compositions, and methods for treatment of androgen-mediated disease |
| HUP1900281A1 (hu) * | 2019-08-06 | 2021-03-01 | Toxie Europe Intelligens Kemiai Szenzorokat Kutato | Monoamin-oxidáz-B gátlók prosztata karcinóma megelõzésében vagy kezelésében történõ alkalmazásra |
| WO2021031991A1 (zh) * | 2019-08-16 | 2021-02-25 | 中国科学院分子细胞科学卓越创新中心 | 治疗激素依赖性疾病及减少激素依赖性疾病患者药物耐受的组合物和方法 |
| WO2021101903A1 (en) | 2019-11-18 | 2021-05-27 | The Regents Of The University Of California | Dual androgen receptor/akr1c3 inhibitors |
| US20230005594A1 (en) * | 2019-12-06 | 2023-01-05 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Clinical decision support for personalized adaptive prostate cancer therapy |
| US10980756B1 (en) | 2020-03-16 | 2021-04-20 | First Wave Bio, Inc. | Methods of treatment |
| CA3192258A1 (en) * | 2020-09-02 | 2022-03-10 | Ascentawits Pharmaceuticals, Ltd. | Akr1c3 detection method, and diagnostic kit for detecting akr1c3 and use thereof |
| WO2022212631A1 (en) * | 2021-03-31 | 2022-10-06 | Taiho Pharmaceutical Co., Ltd. | Treatment of patients metastatic castration-resistant prostate cancer with an androgen receptor antagonist |
| WO2022250466A1 (ko) * | 2021-05-27 | 2022-12-01 | 사회복지법인 삼성생명공익재단 | 전립선암의 엔잘루타미드 저항성 억제용 약학 조성물 및 엔잘루타미드 저항성을 가지는 전립선암 치료용 약학 조성물 |
| CN115721720A (zh) * | 2021-08-31 | 2023-03-03 | 北京大学 | Kras抑制剂与akr抑制剂联用在对抗肿瘤细胞耐药性中的应用 |
| US20240122922A1 (en) * | 2022-09-26 | 2024-04-18 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Methods Of Treating Cancer With Transmembrane Protein 16F (TMEM16F) Inhibitors |
| CN115721629B (zh) * | 2022-10-31 | 2024-02-20 | 西安交通大学 | 多西他赛与恩杂鲁胺联合用药pH响应型铁-铜磁性纳米载药系统及其制备和应用 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5055303A (en) | 1989-01-31 | 1991-10-08 | Kv Pharmaceutical Company | Solid controlled release bioadherent emulsions |
| US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
| US5188837A (en) | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US5254342A (en) | 1991-09-30 | 1993-10-19 | University Of Southern California | Compositions and methods for enhanced transepithelial and transendothelial transport or active agents |
| CA2129514A1 (en) | 1992-03-12 | 1993-09-16 | M. Amin Khan | Controlled released acth containing microspheres |
| US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
| TW385308B (en) | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
| US20030144312A1 (en) | 2001-10-30 | 2003-07-31 | Schoenhard Grant L. | Inhibitors of ABC drug transporters in multidrug resistant cancer cells |
| WO2004004661A2 (en) * | 2002-07-09 | 2004-01-15 | Point Therapeutics, Inc. | Boroproline compound combination therapy |
| KR20050029209A (ko) | 2002-07-15 | 2005-03-24 | 미리어드 제네틱스, 인크. | 화합물, 조성물 및 이의 사용방법 |
| WO2004006906A2 (en) | 2002-07-15 | 2004-01-22 | Combinatorx, Incorporated | Methods for the treatment of neoplasms |
| US20050250709A1 (en) * | 2003-12-19 | 2005-11-10 | Bionaut Pharmaceuticals | Anti-neoplastic agents, combination therapies and related methods |
| US20070009533A1 (en) | 2005-07-06 | 2007-01-11 | Branimir Sikic | Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism |
| US20090035389A1 (en) | 2007-02-23 | 2009-02-05 | Specigen Inc. | Targeted protein cages |
| GB2451875B (en) * | 2007-08-15 | 2012-05-16 | Mono Pumps Ltd | Filtration system |
| WO2009070331A2 (en) | 2007-11-27 | 2009-06-04 | Stc.Unm | Compounds and methods for the selective inhibition of abcb1, abcc1 and abcg2 transporters and the treatment of cancers, especially drug resistant cancers and high throughput flow cytometry assay to detect selective inhibitors |
| EP3062106B1 (en) | 2008-04-16 | 2020-11-11 | The Johns Hopkins University | Method for determining androgen receptor variants in prostate cancer |
| WO2012142208A1 (en) * | 2011-04-13 | 2012-10-18 | The Trustees Of The University Of Pennsylvania | Bifunctional akr1c3 inhibitors/androgen receptor modulators and methods of use thereof |
| US20140294957A1 (en) * | 2011-04-18 | 2014-10-02 | Maxdelbruck-Centrum Fur Molekulare Medizin | Niclosamide for the treatment of cancer metastasis |
| US9346803B2 (en) * | 2011-10-17 | 2016-05-24 | Vanderbilt University | Indomethacin analogs for the treatment of castrate-resistant prostate cancer |
| KR101434461B1 (ko) | 2011-10-21 | 2014-09-01 | 한국생명공학연구원 | 2-하이드록시아릴아마이드 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물 |
| WO2013142390A1 (en) | 2012-03-21 | 2013-09-26 | Gtx, Inc. | Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors |
| JOP20200097A1 (ar) | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
| CN105899223A (zh) | 2013-10-28 | 2016-08-24 | 加利福尼亚大学董事会 | 转移性前列腺癌的治疗 |
| CN104771386A (zh) | 2014-01-10 | 2015-07-15 | 中国科学院广州生物医药与健康研究院 | 苯甲酰胺类化合物及其应用 |
| CN107207417A (zh) | 2014-11-13 | 2017-09-26 | 埃罗米克斯公司 | 新方法 |
| WO2016179002A1 (en) | 2015-05-01 | 2016-11-10 | The Regents Of The University Of California | Compositions and methods for treatment of cancer |
| CN105566147B (zh) | 2015-12-07 | 2018-03-09 | 北京信德润兴科技有限公司 | 一种化合物及其制备方法和用途及相应的靶向给药系统和化疗药物 |
| WO2018136650A1 (en) | 2017-01-19 | 2018-07-26 | The Regents Of The University Of California | Compositions and methods for treating androgen-independent cancer |
-
2014
- 2014-10-27 CN CN201480071520.XA patent/CN105899223A/zh active Pending
- 2014-10-27 EP EP14857072.4A patent/EP3062808B1/en not_active Not-in-force
- 2014-10-27 JP JP2016526801A patent/JP6548641B2/ja not_active Expired - Fee Related
- 2014-10-27 WO PCT/US2014/062455 patent/WO2015065919A1/en not_active Ceased
-
2016
- 2016-04-20 US US15/134,228 patent/US20170315127A1/en not_active Abandoned
-
2019
- 2019-06-25 JP JP2019116833A patent/JP6974392B2/ja not_active Expired - Fee Related
- 2019-10-16 US US16/654,847 patent/US11215617B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016540738A5 (OSRAM) | ||
| JP2014515373A5 (OSRAM) | ||
| WO2012079092A3 (en) | Testosterone undecanoate compositions | |
| JP2014526503A5 (OSRAM) | ||
| HRP20150644T1 (hr) | Metoda za lijeäśenje atrijalne fibrilacije | |
| RU2014111069A (ru) | Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение | |
| MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
| NZ747657A (en) | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative | |
| JP2015500225A5 (OSRAM) | ||
| JP2017529382A5 (OSRAM) | ||
| EA201590166A1 (ru) | Комбинированная терапия для лечения рассеянного склероза | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| HK1198869A1 (en) | Combination treatments for hepatitis c | |
| JP2014516942A5 (OSRAM) | ||
| PE20150161A1 (es) | Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple | |
| JP2020516646A5 (OSRAM) | ||
| JP2014511393A5 (OSRAM) | ||
| JP2017537936A5 (OSRAM) | ||
| EP4609912A3 (en) | New use of a combination of sacubitril and valsartan | |
| JP2013541583A5 (OSRAM) | ||
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| JP2015531373A5 (OSRAM) | ||
| JP2018522920A5 (OSRAM) | ||
| MX380070B (es) | Una composición farmacéutica que comprende amlodipino, valsartán y rosuvastatina. | |
| JP2014504636A5 (OSRAM) |